Amgen Astellas BioPharma was established in October 2013, as a joint venture company of a U.S. based Amgen, Inc. and Astellas Pharma Inc. with its mission, “To deliver breakthrough-science-based medicines and contribute exceptional value for Japanese patients in order to create a healthy society”. Since then it has continued its challenge to actualize this mission.
In the 20th century, a number of break-through science occurred such as in aircrafts, electronics, and computers that majorly affected people’s lives.
Today, in the 21th century, a similar scale of innovation is taking place in life-science, especially in the research and development of medicines based on insights from human genetics. We are indeed living in the beginning of the “BioCentury”.
Amgen Astellas BioPharma operates daily to bring health, a fundamental human needs, by addressing unmet medical needs specifically in the areas with limited therapeutic options. We believe that the break-through science products we try to deliver to those individual patients and healthcare providers will ingenerate a larger impact than the changes that physics and engineering brought to us in the 20th century. In order to assure this difference, we have established our understanding of Japanese healthcare, as well as knowledge of marketing, development, and regulatory based on those built by Astellas through the years of its practice in Japan.
It is our passion, as employees of Amgen Astellas BioPharma living in the “BioCentury”, to deliver new values to the Japanese patients by collaborating strengths of Amgen and Astellas.
Representative Director, Amgen Astellas BioPharma K.K.
Steve Sugino Bio
Steve Sugino became Vice President of Amgen Inc. and General Manager of Amgen Astellas BioPharma (Amgen Astellas) in April 2017. As of June 1, 2017, he has been appointed as the President and Representative Director of Amgen Astellas. Prior to this role, he worked over 20 years in the pharmaceutical industry where he held various roles of increasing responsibility in general management, sales and marketing, clinical development, business development and alliance management in both Japan and the US.
Sugino, a fourth generation of Japanese-American, graduated with a degree in Asian Studies from the University of California, Santa Barbara and started his career at the Bank of Tokyo in Japan before moving to Credit Suisse First Boston as an investment banker in both Tokyo and New York. He led Sanofi Japan’s diabetes business. At Eli Lilly, he held a global brand development role for the neuroscience portfolio and other neuroscience molecules, working out of the US headquarters. His last role at Eli Lilly was Vice President of US diabetes commercial. He was most recently Head of Asia Pacific, and President and Representative Director of Japan for Biogen where he was responsible for all aspects of Biogen’s operations across the Asia Pacific region and for the fully integrated Japan affiliate.